Geographic Atrophy: What to Look For and When to Refer - Baseline Assessment

Launch Date:
March 22, 2022
Expiration Date:
The accreditation for this activity has expired.
Return to Enrollment Page

Primary Audience:

Optometrists

Relevant Terms:

AMD, Geographic Atrophy, Retina

OVERVIEW

Recognition & Referral: Best Practices for Managing Patients with GA: Baseline Assessment

FACULTY

Roger A. Goldberg, MD, MBA​

Vitreoretinal Specialist​
Bay Area Retina Associates​
Walnut Creek, CA​
Volunteer Faculty​
California Pacific Medical Center​
Ophthalmology Residency​
San Francisco, CA

LEARNING OBJECTIVES

1.
Articulate the burden of illness linked to geographic atrophy (GA)​
2.
Describe disease detection and factors influencing progression​  
3.
Discuss the prevalence of age-related macular degeneration​
4.
Review the therapeutic interventions that have been explored as well as those in the pipeline  ​
5.
Understand the pathogenesis of GA​  

GENERAL INFORMATION

The following faculty/staff members have the following financial relationships with commercial interests:​

Roger A. Goldberg, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Allergan, Apellis, Carl Zeiss Meditec, Chengdu, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan, and Genentech.​​

The Evolve staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.​